Receptionist working behind a glass-partitioned desk with a “Check In Here First” sign and a staff schedule on a corkboard.
Interior of the Maria X Martinez Health Resource Center in SoMa. Photo courtesy of the San Francisco Department of Public Health

In 2024, a man in his 40s who had used fentanyl daily for years came to UCSF addiction specialist Dr. Sarah Rosenwohl-Mack with a question. A friend had started addiction treatment with an injection of buprenorphine, a medication that reduces opioid cravings and withdrawal symptoms. It had gone well. Could he try it, too?

Other addiction treatments — methadone, buprenorphine tablets and residential treatment — hadn’t worked for him.

Buprenorphine tablets, first approved to treat opioid addiction in the United States in 2002, had been used to help people using heroin manage cravings and withdrawal symptoms, like vomiting, diarrhea and intense body aches.

But as fentanyl came to dominate the illicit opioid supply across much of the country in the late 2010s, starting addiction treatment with buprenorphine became more difficult.

Fentanyl lingers more unpredictably in the body than heroin, and taking buprenorphine tablets too soon can trigger a sudden, brutal withdrawal instead of providing relief.

But, that day, Rosenwohl-Mack was able to give her patient a buprenorphine injection, a formulation that was newly available at her clinic. When she called to check on him the next morning, he told her he’d had “a little bit of a rough night.” But he felt great. 

Two days later, the man returned for another injection, this time designed to last in his body for a month. “He was one of those early patients who showed me, oh, you know, this is working and this is what people want,” said the doctor. “Let’s see if we can do it.” 

San Francisco is trying to give more people more immediate access to injectable buprenorphine for fentanyl addiction. A $500,000 pilot launched Nov. 2 at the Maria X Martinez Health Resource Center, a city clinic in SoMa, allows clinicians there to stock and administer the injections onsite for the first time.

Buprenorphine is an opioid medication that partly activates the same brain receptors as fentanyl. By doing so, it reduces cravings and withdrawal symptoms without producing fentanyl’s high or extreme sedation.

Both buprenorphine and methadone, a much older medication used to treat opioid addiction, reduce the risk of death by about 50 percent, according to Rosenwohl-Mack.

Now newer injectable formulations of buprenorphine offer a potentially easier way to begin treatment. Under certain protocols, patients can even receive their first injection while still using fentanyl — rather than first having to endure withdrawal, a prospect that often discourages people from seeking help.

Withdrawal can bring vomiting, diarrhea, chills, intense muscle aches and anxiety. Starting conventional buprenorphine in tablet or film form too soon after using fentanyl carries another risk: precipitated withdrawal, a sudden worsening of symptoms when the medication displaces fentanyl from receptors in the brain. 

In a 2024 study of 22 people who used opioids in Los Angeles, one woman who experienced precipitated withdrawal after taking conventional buprenorphine too soon described it as “the worst sick I’ve ever been.” 

“That’s the real innovation of the injections,” said Rosenwohl-Mack, who advised the S.F. pilot program on planning, implementation and dosing protocols. “It’s a way to start treatment that is much more possible for our patients.”

The Maria X Martinez walk-in clinic receives about 21,000 patient visits annually, and more than three-quarters of its clients experience homelessness. Patients visit for everything from wound care to dental services and addiction treatment.

Previously, someone seeking a long-acting injection at the Martinez clinic had to go elsewhere. But that detour could mean losing an opportunity to begin treatment.

Dr. Tanya Majumder, the clinic’s medical director, said patients’ willingness to begin treatment can be fleeting — sometimes lasting only half an hour or an hour. Having the medication on hand means clinicians can act immediately when a patient expresses readiness to stop using fentanyl, rather than waiting for them to return another day.

The injections also eliminate the need to take daily medication, or to safeguard pills, which can be particularly challenging for people experiencing homelessness, Majumder said.

The pilot is budgeted for 460 starting doses and 500 follow-up doses over two years. The city plans to track treatment retention, overdoses, emergency department visits and hospitalizations associated with the pilot through April 2028, with plans to expand the use of injectable buprenorphine to as many as five additional clinics in 2027.

The pilot project is funded largely through Breaking the Cycle, a public-private fund launched by Mayor Daniel Lurie to support the city’s homelessness and behavioral health initiatives. 

A different way to start treatment

Rosenwohl-Mack led a 2025 study examining 131 instances in which patients began treatment with buprenorphine injections at San Francisco and Oakland safety-net clinics. She found that in 43 percent of cases, patients who began treatment with injections remained on buprenorphine for the next three months.

She called the result “encouraging,” given that many patients were experiencing homelessness or unstable housing, making it difficult to take daily medication and stay in treatment.

A 2018 randomized trial involving 428 patients at U.S. outpatient clinics found that weekly and monthly injections were at least as effective as daily medication at reducing illicit opioid use and staying in treatment. A 2024 follow-up analysis found that extended-release injections could provide an advantage in reducing fentanyl use.  

Dr. Gail D’Onofrio, a Yale University emergency medicine professor who studies addiction, said that it is important to offer patients different treatment options to overcome opioid addiction.

“There isn’t ‘one size fits all,’” she said. 

Rosenwohl-Mack said same-day access to buprenorphine injections remains difficult nationally, with many cities lacking the infrastructure to provide it immediately. She called San Francisco’s efforts to expand access to the injections “phenomenal.” 

She says the man she treated in 2024 showed her what a difference the treatment can make. While he’s had ups and downs with treatment since then, she said, he remains on buprenorphine. 

After receiving his first injections, he told her the shot was the “smoothest” experience he’d ever had starting buprenorphine treatment.

“‘Oh my God, my friend was totally right,’” Rosenwohl-Mack recalled him saying. “‘I’m going to go tell everyone else.’” 

Sarah Hopkins reports on SoMa, Mission Bay and other matters for Mission Local.

With a background in science writing, she has reported on environmental justice, climate change, technology and intersections between science, politics and law. She earned a master's degree from MIT's science journalism program in 2024.

Her reporting has appeared in the Guardian, Inside Climate News and Undark Magazine, among other publications. She is fluent in Spanish.

You can reach her securely on Signal @sarah.270.

Leave a comment

Please keep your comments short and civil. Do not leave multiple comments under multiple names on one article. We will zap comments that fail to adhere to these short and easy-to-follow rules.

Your email address will not be published. Required fields are marked *